Amgen, GSK Pediatric Oncology Studies Could Change Based on Advisory Committee Comments
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s pediatric oncology subcommittee will consider the best study designs to isolate pediatric clinical benefit in Amgen’s blinatumomab and whether pediatric use can be extrapolated from adult data in GSK’s trametinib.